{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010924","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.780649+00:00","generated_at":"2026-06-17T09:06:24.961654+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eledon reports Q4 2022 net loss of $58.4M, including $48.6M goodwill impairment; refocuses on kidney transplant","bullets":["Q4 2022 net loss $58.4M ($4.09/share) vs $8.8M ($0.59) in Q4 2021; full-year net loss $88.0M ($6.16) vs $34.5M ($2.33).","Cash and equivalents $56.4M at Dec 31, 2022; expected to fund operations into Q1 2024.","Phase 1b kidney transplant trial dosed fourth patient; data on first three to be presented at WCN March 31, 2023.","Deprioritized IgAN program and discontinued islet cell trial; collaboration with eGenesis for xenotransplantation.","Subject to financing, Phase 2 BESTOW trial of tegoprubart in kidney transplant expected to initiate mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010924","json":"https://secwatch.observer/filing/0000950170-23-010924.json","markdown":"https://secwatch.observer/filing/0000950170-23-010924.md","text":"https://secwatch.observer/filing/0000950170-23-010924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023010924/0000950170-23-010924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023010924/eldn-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:06:24.961654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93aeaa64d623da585bdb7891d8c44eab2792fc68","claim":"Eledon Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: net income net loss of $88.0 million, or $6.16 per share.","evidence_excerpt":"The Company reported a net loss of $88.0 million, or $6.16 per share, for the year ended December 31, 2022, compared to a net loss of $34.5 million, or $2.33 per share, in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023010924/0000950170-23-010924-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"net loss of $88.0 million, or $6.16 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9e768d5a167c928c6fc67160d7fe958bd6ab67e8","claim":"Eledon Pharmaceuticals, Inc. reported the four months ended December 31, 2022 results: net income net loss of $58.4 million, or $4.09 per share.","evidence_excerpt":"The Company reported a net loss of $58.4 million, or $4.09 per share, for the three months ended December 31, 2022, compared to a net loss of $8.8 million, or $0.59 per share, for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023010924/0000950170-23-010924-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the four months ended December 31, 2022"},{"label":"Net income","value":"net loss of $58.4 million, or $4.09 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}